refractory temporal lobe epilepsy | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

18,876 results for “refractory temporal lobe epilepsy”

Trials

View all 15740 →

Transcranial Electrical Stimulation Targeting the Cerebellum for the Treatment of Refractory Temporal Lobe Epilepsy

60 participants · First posted Aug 19, 2024

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

12 participants · First posted Oct 3, 2023

Enrolling By Invitation

Low-Intensity Focused Ultrasound Neuromodulation for Epilepsy

6 participants · First posted Jan 21, 2026

Drugs

View all 111 →

undisclosed gene therapy (AAV, temporal lobe epilepsy)

AMT-260

SRXXX (Epilepsy)

Manufacturer: Shanghai SIMR Biotech Co., Ltd.

Conditions: Epilepsy

Organizations

View all 35 →

Lobe Sciences Ltd.

Canada

EPILEPSY FOUNDATION OF AMERICA

United States

Korean Epilepsy Society

South Korea

News

View all 2990 →

uniQure Doses First Patient in Phase I/IIa Trial of AMT-260 for Refractory Mesial Temporal Lobe Epilepsy

uniQure Doses First Patient in Phase I/IIa Trial of AMT-260 for Refractory Mesial Temporal Lobe Epilepsy

uniQure's Gene Therapy AMT-260 Achieves 92% Seizure Reduction in First Drug-Resistant Epilepsy Patient

Page 1 of 1888